Vericel to Present at 15th Annual Needham Healthcare Conference
08 April 2016 - 10:30PM
Vericel Corporation (Nasdaq:VCEL), a leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced that Nick
Colangelo, president and CEO, will present at the 15th Annual
Needham Healthcare Conference at The Westin Grand Central Hotel in
New York, NY on Tuesday, April 12, 2016, at 9:20am Eastern time.
The presentation will be webcast live and may be accessed from
the news and events section of the Vericel
website: http://wsw.com/webcast/needham76/vcel.
About Vericel Corporation
Vericel Corporation is a leader in developing patient-specific
expanded cellular therapies for use in the treatment of patients
with severe diseases and conditions. The company markets two
autologous cell therapy products in the United States: Carticel®
(autologous cultured chondrocytes), an autologous chondrocyte
implant for the treatment of cartilage defects in the knee, and
Epicel® (cultured epidermal autografts), a permanent skin
replacement for the treatment of patients with deep-dermal or
full-thickness burns comprising greater than or equal to 30 percent
of total body surface area. Vericel is also developing MACI™, a
third-generation autologous chondrocyte implant for the treatment
of cartilage defects in the knee, and ixmyelocel-T, a
patient-specific multicellular therapy for the treatment of
advanced heart failure due to ischemic dilated
cardiomyopathy. For more information, please visit the
company's website at www.vcel.com.
CONTACT: Chad Rubin
The Trout
Group
crubin@troutgroup.com
(646) 378-2947
or
Lee
Stern The Trout
Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From May 2023 to May 2024